๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 11 Shijiazhuang 1 Zhengzhou 1 Jinan 1 Chengdu 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin11 Shijiazhuang1 Zhengzhou1 Jinan1 Chengdu1
All 6 locations
Target enrolment
to

Trials with a site in Tianjin

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT07490288AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
27
Tianjin
2026-05-08
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839AML, IDH1 Mutation, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Active, closed
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
NCT06744556AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
41
Tianjin
2025-01-21
Recruiting
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
NCT06744504AML, RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
284
Tianjin
2025-01-10
Recruiting
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
NCT06561880FLT3 Gene Mutation, AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
66
Tianjin
2024-10-08
Recruiting
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
NCT06529250AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
148
Tianjin
2024-08-13
Recruiting
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
NCT06386302AML, Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
184
Tianjin
2024-08-05
Recruiting
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
NCT06265545AML, Refractory, Relapsed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
458
Tianjin
2024-02-22
Active, closed
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
NCT03021330AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
1,100
Tianjin
2017-02-08
Active, closed
Efficacy and Safety of Chidamide in CBF Leukemia
NCT03031262AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
250
Tianjin
2017-02-08
By invitation
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
NCT03031249AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
80
Tianjin
2017-02-08
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

7 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 11 studies
PhaseStudiesRecruitingShare
Not applicable4436.4%
Phase 1/24236.4%
Phase 32118.2%
Phase 2109.1%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China117
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.